This survey covers the main developments in the pharmaceutical sector in the European Union over the period 2017–2018.1 This past year has been rich in developments, the most noticeable of which were the confirmation of the competition authorities' interest in excessive pricing cases and the Court of Justice of the European Union (CJEU) landmark judgment in the Hoffmann-La Roche case. Patent settlement appeals against the European Commission (Commission) and the UK Competition and Markets Authority (CMA) decisions have continued, with significant judgments expected in 2018–2019, which will help clarify the law. On the merger control front, the treatment of innovation in merger cases has continued to be an important topic.
Click here to download the full PDF.
Click here to view our US report.
1 This review covers the period between September 2017 and April 2018.
This article was previously published by Global Competition Review in The European, Middle Eastern and African Antitrust Review 2019.
This publication is provided for your convenience and does not constitute legal advice. This publication is protected by copyright.
© 2018 White & Case LLP
